Home › Trials › NCT06826677

Using Durvalumab for Extensive-Stage Small Cell Lung Cancer

REAL-WORLD CLINICAL OUTCOMES AMONG PATIENTS INCLUDED IN AN EARLY ACCESS PROGRAMME TREATED WITH DURVALUMAB IN COMBINATION WITH PLATINUM AND ETOPOSIDE AS FIRST-LINE THERAPY IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER: AN ITALIAN MULTICENTER OBSERVATIONAL STUDY

Observational AstraZeneca · NCT06826677

This study looks at how well durvalumab works and how safe it is for people with extensive-stage small cell lung cancer who have already received this treatment.

Quick facts

Study typeObservational
Enrollment90 (estimated)
SexAll
SponsorAstraZeneca Industry-sponsored
Drugs / interventionsdurvalumab, atezolizumab, chemotherapy, immunotherapy
Locations13 sites (Bologna and 12 other locations)
Trial IDNCT06826677 on ClinicalTrials.gov

What this trial studies

This observational study focuses on patients with extensive-stage small cell lung cancer (ES-SCLC) who have previously received durvalumab treatment through an early access program. It aims to gather real-world data on the effectiveness and safety of durvalumab in this patient population. The study will analyze patient outcomes and treatment responses to better understand the potential benefits of durvalumab in managing ES-SCLC. By leveraging data from patients treated in Italy, the study seeks to provide insights into the real-world application of this therapy.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 and older who have been diagnosed with extensive-stage small cell lung cancer and have received durvalumab treatment.

Not a fit: Patients who do not have a medical chart available or have not received durvalumab treatment will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide valuable information on the effectiveness of durvalumab in improving outcomes for patients with extensive-stage small cell lung cancer.

How similar studies have performed: Other studies have shown promise in using immunotherapy for small cell lung cancer, but this specific approach with durvalumab in a real-world setting is relatively novel.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Patients with diagnosis of extensive-stage Small Cell Lung Cancer (ES-SCLC).
2. Patients entered, at least 24 months prior to the study inclusion, the D419QR00007 Early Access Programme (CASPIAN EAP) implemented in Italy.
3. Adult patients (aged ≥ 18 years) at the time of inclusion in the CASPIAN EAP.
4. Patients having performed at least one administration of durvalumab treatment in the CASPIAN EAP.
5. Patients (or their legally acceptable representatives) who have signed the subject informed consent and privacy form, if applicable.

Exclusion Criteria:

1. Patients with unavailable medical chart.

Where this trial is running

Bologna and 12 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Small Cell Lung Carcinoma
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.